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Background: Hypertension is often complicated by increased arterial stiffness and is an
independent predictor of adverse cardiovascular (CV) outcome. Beta blockers and angio-
tensin receptor blockers (ARBs) are commonly used antihypertensive agents. The effect of
beta blockers and ARBs on arterial stiffness has not been compared adequately. The aim of
the present study is to compare the effect of telmisartan with metoprolol on arterial
stiffness in hypertensive patients in prospective open label randomized parallel group
intervention study.
Methods: 100 patients of hypertension, not on any antihypertensive agents, were enrolled
after obtaining informed consent. Baseline recording of data related to demographics, CV
risk factors, anthropometry and BP were made. Arterial stiffness was measured non-
invasively by recording pulse wave velocity (PWV) using periscope (Genesis medical
system). Left ventricular (LV) mass was measured using 2D guided M-mode echocardi-
ography. Blood sugar, renal function, lipids and uric acid estimations were done in fasting
state. Patients were randomized to receive metoprolol and telmisartan using stratified
randomization technique. Dose of the study drugs were titrated to achieve target BP of
<140/90 mmHg. Data related to PWV, BP, anthropometry and blood biochemistry was
repeated after 6 months of treatment with study drugs.
Results: Telmisartan resulted in significantly greater reduction in arterial stiffness index
(ASI) in left and right lower limb arterial bed (39.9 ± 11.7 vs. 46.8 ± 17.0 m/s, p < 0.02) and
(36.4 ± 9.6 vs. 44.86 ± 15.1 m/s, p < 0.002) respectively and systolic blood pressure (SBP)
(4.9 mmHg with 95% C.I. of 8.0e1.7 mmHg, p < 0.003) compared to metoprolol. Reduction
in diastolic blood pressure (DBP) in telmisartan and metoprolol groups was not different2.
(M. Sumbria).
ociety of India. All rights reserved.
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 4 1 5e4 2 1416statistically (1.0 mmHg with 95% C.I. of 3.3e1.2 mmHg, p < 0.3). The change in LV mass
was not significantly different between the study groups (135.5 ± 37.6 vs. 143.2 ± 41.5,
p < 0.3).
Copyright © 2014, Cardiological Society of India. All rights reserved.1. Introduction
Cardiovascular diseases (CVD) are the leading cause of
morbidity and mortality and contribute to about 30% of the
total mortality. Hypertension ranks number one as a risk
factor for non-communicable diseases related disability-
adjusted life years (DALYS).1 The underlying cause of
morbidity and mortality in hypertension is primarily due to
vascular damage thus affecting heart, brain and kidneys. In
hypertension, the structure and function of the arterial wall
have been reported to be altered even in an early stage of the
disease resulting in increased arterial stiffness.2,3 Increased
arterial stiffness is very important risk marker of CVD in
patients of hypertension.4e9 The stability, resilience and
compliance of the vascular wall are dependent on relative
contributions of its two prominent scaffolding proteins:
collagen and elastin.10e13 The relative content of these mol-
ecules is normally held stable by slow but dynamic process of
production and degradation. Dysregulation of this balance
mainly due to stimulation of inflammatory milieu, leads to
overproduction of abnormal collagen and diminished quan-
tities of normal elastin which contribute to vascular stiffness.
Stiffness is not uniformly distributed throughout the vascular
tree but is often patchy.14 Increased arterial stiffness leads to
increased systolic and lower diastolic pressure in the central
aortic artery. This translates into increased ventricular
afterload and decreased coronary perfusion pressure leading
to left ventricular hypertrophy (LVH) and subendocardial
ischemia. Thus, LVH and subendocardial ischemia could
trigger the onset of hypertensive heart disease. Increased
systolic pressure in central aorta and conduit arterial tree as
a result of increased arterial stiffness, leads to decreased
impedance gradient between major conduit arterial tree and
distal small resistant arterial bed.15e18 Thus, transmission of
increased arterial pressure from central arterial tree to distal
microcirculatory bed could also play a role in hypertensive
microangiopathy. Therefore, management of hypertension
should address not only the control of BP, but also should aim
to prevent progression or reverse the process of arterial
stiffness that would be more effective means to reduce the
risk of CVD. The available antihypertensive agents lower the
BP through diverse mechanisms. The arterial stiffness has
been documented to decrease with use of Angiotensin con-
verting enzyme inhibitors (ACE-Is) and ARB19,20 but there
were conflicting results with beta-blockers and diuretics in
number of small studies.21 These studies are limited by
shorter duration of treatment and limited comparative trials.
Beta-blockers and ARBs have favorable effect on structural
remodeling of heart in congestive heart failure, however
there are no studies comparing their effect on arterial stiff-
ness in patients of hypertension. Present study compared the
effect of metoprolol and telmisartan on arterial stiffness asmeasured by PWV in newly diagnosed and or diagnosed hy-
pertensive not on antihypertensive agents.2. Methods
2.1. Study design
Prospective, randomized, parallel group, open label, blinded,
end point clinical intervention trial in hypertensive patients.
Investigator measuring the PWV was blinded for the assigned
treatment group.
2.2. Patient population screened
All consecutive patients of newly diagnosed and established
hypertension not on antihypertensive agents attending Car-
diology OPD of IGMC hospital were screened for enrollment in
the study.
2.3. Patient selection
Patients of newly detected hypertension i.e. recording of
BP > 140/90 mmHg on two different occasions at 2e4 weeks
interval first time, or known hypertensives but not on anti-
hypertensive medications with BP > 140/90 mmHg were
enrolled if found eligible after obtaining informed consent.
Hypertensive patients with peripheral vascular disease, Heart
failure, Heart rate (HR) less than 70/minutes, cerebrovascular
accident, chronic kidney disease, Bronchial asthma, signifi-
cant chronic obstructive airway disease, patients with atrial
fibrillations and those on antihypertensive agents were
excluded. The study protocol was approved by Institutional
ethical committee.
Sample size; as a pilot study 106 eligible patients con-
senting to participate were enrolled for the study.
2.4. Data collection
Data related to demographics and status of CV risk factors
recorded using structured questionnaires, followed by clinical
examination to record BP using mercury sphygmomanom-
eter. Average of two readings, recorded at an interval of
3e5 min, using appropriate size BP cuff, following standard
guidelines were taken as the BP value. Anthropometric mea-
surement included weight, height and waist circumference
using standard procedure. About 7e8 cc venous blood was
drawn after overnight fasting for estimation of blood urea,
creatinine, uric acid and lipid profile using standard kits in
fully automatic auto analyzer, KONE LAB-30. Blood sugar was
estimated by GOD POD method (glucose oxidase peroxidase
method) on semiautomatic analyzer, ERBA CHEM 5 plus by
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PWV in both brachial and femoral arteries noninvasively with
PERISCOPE™ (Genesis Medical Systems) based on oscillo-
metric principle. Arterial stiffness value in carotid femoral
arterial segment was calculated automatically by inbuilt
software of periscope.
2.5. Measurement of LV mass
LV mass was measured using 2D guided M mode scan in
parasternal long axis view at the level of tip of mitral leaflets
following the standard guidelines of American Society of
Echocardiography (ASE) for calculating LVmass by measuring
(intact ventricular septum) IVS, left ventricular internal
dimension (LVID) and LV posterior wall thickness at end of
diastole using I E 33 Echo machine of Philips medical System
with adult phased array probe.
2.6. Estimation of arterial stiffness
Arterial stiffness was measured by recording PWV and ASI
noninvasively using oscillometric principle with PERISCOPE™
(Genesis Medical Systems). The subject wasmade to lie on the
bed for at least 10 min in quit room at comfortable tempera-
ture. BP cuffs were wrapped around both upper and lower
limbs and 4 ECG electrodes were applied at standard positions
over anterior chest wall to record ECG signals to obtain ECG
gated trigger for simultaneous inflation of BP cuff in all four
limbs for detection of pulse wave signals by oscillometric
method. Before performing the test, the nature of the proce-
dure was explained to allay the anxiety and was instructed to
refrain from coffee and tobacco smoking at least for 3 h before
study. Following parameters were recorded as indices of
arterial stiffness.
2.7. Pulse wave velocity
PWV was measured by recording of pulse transit time
measured from R wave of ECG signals to the foot of the pulse
wave recorded at left and right brachial artery and left and
right ankle arteries through ECG triggered simultaneous
inflation of BP Cuffs at these sites by inbuilt calibrating
software.
2.8. Arterial stiffness index (ASI)
It is another measure of arterial stiffness. It quantifies the
shape of oscillometric envelope. As the arterial stiffness in-
creases, it becomes harder to collapse the arteries by applying
pressure. Hence the oscillometric envelope becomes flatter as
the stiffness increases. The higher the stiffness, higher the ASI
value.
2.9. Randomization procedure
Randomization was stratified for age and sex with blocks of
age groups at 5-years age interval for each gender. The treat-
ment codes for each stratified groups were assigned in
random order using random number table. The investigator
implementing the assigned treatment code was blinded forthe allocation sequence. After baseline evaluation patients
were randomized to telmisartan ormetoprolol group choosing
the appropriate block based on given age and sex of the pa-
tient and the treatment was assigned based on generated
allocation sequence on the given block. Starting dose of
metoprolol was 25 mge50 mg and was 20 mge40 mg in tel-
misartan group depending upon baseline BP and HR. Patients
were followed up within 2 weeks time to titrate the dose in
both arms to ensure control of BP by 4 weeks time. Maximum
dose of metoprolol used was 200 mg and 160 mg of telmi-
sartan. Patients were followed up for 6months. At the end of 6
months of study drug exposure each patients underwent
repeat recording of BP, anthropometry, estimation of blood
sugar, blood urea, creatinine, uric acid, lipid profile, PWV and
Echo study for estimation of LV mass using same protocol.
Patients in both study groupswere counseled to adopt healthy
lifestyle as a part of usual practice.
2.10. Statistical analysis
It was a pilot study and 50 patients in each group were
enrolled to compare the effect on arterial stiffness. The de-
mographic and clinical characteristics of the study population
in each groupwas described as percentages andmean± SD for
categorical and continuous variables respectively and differ-
ences in the distribution between two study groups were
compared by X2 and unpaired t test or Mann Whitney test as
appropriate. The effect of study drugs on arterial stiffness was
compared using unpaired t test or Man Whitney test as
appropriate with estimation of 95% C.I. of the effect size. 2
tailed significance at <0.05 were considered as statistically
significant. Statistical analysis were done using Epi info
version 3.4.3. Results
3.1. Patient enrollment and dropouts
A total of 106 patients were enrolled, 100 completed the study
follow up. Total of 6 patients were lost to follow up as 3 pa-
tients dropped out from each study group. In telmisartan
group 2 patients discontinued medicines in between as they
felt better after briefly taking medicines and another patient
diagnosed as a case on lung carcinomawhereas in metoprolol
group 1 patient was withdrawn from study as he complained
of weakness due to study drug and 2 patients were lost to
follow up.
3.2. Demographic and clinical characteristics of the
study population
The characteristics of the study population in metoprolol and
telmisartan groups are described. The two study groups were
well matched for age (45.0 ± 10.6 vs. 45.0 ± 10.3, p 0.67) and
gender distribution; men (69.1% vs. 76.5%, p 0.39). The distri-
bution of CV risk factors; overweight and obesity (32.7% vs.
33.3%, p 0.95), dyslipidemia (78.2% vs. 82.4%, p 0.59), diabetes
(3.6% vs. 2.0%, p 0.60) and tobacco consumers was also similar
in two study groups (38.2% vs. 37.3%, p 0.92). The median dose
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respectively with range of 25e200 mg for metoprolol and
20e160 mg for telmisartan (Table 1).
3.3. Distribution of impaired arterial stiffness index
Frequency distribution of impaired arterial stiffness was
similar in two study groups, but varied greatly in different
arterial territories and was highest in carotid femoral arterial
segment (78.2 vs. 78.4%, p 0.98) followed by in lower limb; left
ankle (7.3% vs. 5.9%, p 0.77), right ankle (7.3% vs. 2.0%, p 0.2)
and least in upper limb arterial segments; right brachial (3.6%
vs. 2.0%, p 0.60), left brachial (0.0% vs. 2.0%, p 0.30) in meto-
prolol and telmisartan group respectively (Table 1).
3.4. Study groups means of cardio metabolic risk
factors, serum levels of blood urea, creatinine, uric acid and
lipids in the study groups
The study groups were well matched for distribution of
various cardio metabolic risk factors, indices of renal function
and uric acid levels. In brief mean level of SBP, (151.5 ± 13.5 vs.
157.8 ± 20.0, p 0.60) DBP (99.6 ± 8.2 vs. 99.6 ± 11.3, p 0.98), HR
(82.1 ± 13.8 vs. 78.1 ± 13.4, p 0.14), LV Mass (134.9 ± 28.5 vs.
129.4 ± 33.2, p 0.36), BMI (26.1 ± 3.9 vs. 25.7 ± 4.3, p 0.60), waist
circumference (93.6 ± 6.7 vs. 91.9 ± 9.8, p 0.31), blood sugar
levels were similar in two groups (93.5 ± 18.0 vs. 94.9 ± 21.4, p
0.70). Themean total cholesterol level was significantly higher
in metoprolol group (203.4 ± 45.7 vs. 185.3 ± 35.7, p < 0.02)
(Table 2).
3.5. Study groups means of PWV in different arterial
territories at baseline
The means of PWV in different arterial segments in meto-
prolol and telmisartan groups were similar at baselineTable 1 e Baseline characteristics of the study groups.
Characteristics Metoprolol
group n ¼ 50
Telmisartan
group n ¼ 50
Sig. at 2
tailed
Age (mean ± SD) 45.0 ± 10.6 45.0 ± 10.3 0.67
Sex (male) % 38 (69.1%) 39 (76.5%) 0.39
Overweight/obesity 18 (32.7%) 17 (33.3%) 0.95
Central obesity 46 (83.6%) 33 (64.7%) 0.02
Dyslipidemia 43 (78.2%) 42 (82.4%) 0.59
Diabetes 2 (3.6%) 1 (2.0%) 0.60
Impaired fasting glucose 3 (5.5%) 5 (9.8%) 0.39
Tobacco consumers 21 (38.2%) 19 (37.3%) 0.92
Family H/O hypertension 27 (49.1%) 21 (41.2%) 0.41
Increased arterial stiffness %
Right brachial artery 2 (3.6%) 1 (2.0%) 0.60
Left brachial artery
stiffness
0 (0%) 1 (2.0%) 0.29
Right lower limb arterial
stiffness
4 (7.3%) 1 (2.0%) 0.20
Left lower limb arterial
stiffness
4 (7.3%) 3 (5.9%) 0.77
Carotid femoral arterial
stiffness
43 (78.2%) 40 (78.4%) 0.98(Table 3.) right brachial artery (34.9 ± 10.6 vs.33.2 ± 10.6 m/s, p
0.59), left brachial artery (30.0 ± 8.0 vs. 31.2 ± 9.2 m/s, p 0.48),
right ankle (41.2 ± 19.7 vs. 44.5 ± 12.3m/s, p 0.31) and left ankle
(45.2 ± 17.7 vs.47.7 ± 19.5 m/s, p 0.83) and carotid femoral ar-
tery (1072.4 ± 366.7 vs. 1043.7 ± 465 m/s, p 0.72) respectively
(Table 3).3.6. Comparison of effect of metoprolol and telmisartan
on arterial stiffness, BP and LV mass
 Brachial artery stiffness Index; Brachial artery stiffness
index in right brachial artery was not significantly different
among telmisartan and metoprolol group (33.6 ± 16.8 vs.
34.3 ± 12.4 m/s, p 0.84. but there was trend of greater
reduction in left brachial artery stiffness in telmisartan
group compared tometoprolol (29.05± 7.8 vs. 32.9 ± 11.6m/
s, p < 0.055).
 Lower limb Arterial Stiffness Index; Both left and right
lower limb arterial stiffness indices decreased significantly
in telmisartan group compared to metoprolol group
(39.9 ± 11.7 vs. 46.8 ± 17.0 m/s, p < 0.023) and (36.4 ± 9.6 vs.
44.8 ± 15.1 m/s, p < 0.002) respectively.
 Carotid femoral pulse wave velocity (CFPWV); There was
no significant difference in CFPWV between telmisartan
andmetoprolol study groups (1011± 337.8 vs. 1045 ± 694m/
s, p < 0.75) although there was a trend in favor of telmi-
sartan group.
 BP; Reduction in SBP was significantly higher in telmi-
sartan group compared to metoprolol group (124.7 ± 7.8 vs.
129.7 ± 7.9, p < 0.003) but no significant difference in the
reduction in DBP was observed between study groups
(81.3 ± 5.4 vs. 82.4 ± 5.9, p < 0.35).
 HR; The mean HR was significantly lower in metoprolol
group than telmisartan group as was expected 67.6 ± 8.5 vs.
78.2 ± 10.4 p < 0.001.
 LV Mass; Although there was a trend of greater reduction
in mean LV mass in telmisartan group than in metoprolol
group but was statistically not significant (135.5 ± 37.6 vs.
143.2 ± 41.5, p 0.33) Table 4.Table 2 e Baseline comparison of population means of
the CV risk factors and indices of renal function in the
study groups.
Characteristics Metoprolol
(mean ± SD)
Telmisartan
(mean ± SD)
p Value
BMI 26.1 ± 3.9 25.7 ± 4.3 0.6
Waist circumference 93.6 ± 6.7 91.9 ± 9.8 0.31
SBP 151.5 ± 13.5 157.8 ± 20.0 0.06
DBP 99.6 ± 8.2 99.6 ± 11.3 0.98
LV mass 134.9 ± 28.5 129.4 ± 33.2 0.36
Fasting blood sugar 93.5 ± 18.0 94.9 ± 21.4 0.70
Total cholesterol 203.5 ± 45.7 185.3 ± 35.7 0.02
LDL-C 122.4 ± 35.9 108.4 ± 27.1 0.02
HDL-C 46.9 ± 11.2 45.7 ± 10.4 0.60
TG 179.6 ± 95.7 176.0 ± 71.6 0.86
TG/HDL ratio 4.0 ± 2.1 3.9 ± 2.0 0.89
Blood urea 28.7 ± 7.0 28.3 ± 6.8 0.73
S. creatinine 0.87 ± 0.18 0.87 ± 0.18 0.93
Uric acid 6.1 ± 1.3 6.4 ± 1.5 0.28
Table 3 e Baseline comparison of study groups means of arterial stiffness (PWV) in different regional.
Regional arterial segments Metoprolol
meters
Telmisartan
meters
Mean difference
on meters
95% C.I. of mean
difference
Right brachial artery 34.9 ± 20.6 33.2 ± 10.6 1.73 4.6e8.1
Left brachial artery 30.0 ± 8.0 31.2 ± 9.2 1.2 4.4e2.1
Right ankle 41.2 ± 19.7 44.5 ± 12.3 3.2 9.6e3.7
Left ankle 45.2 ± 17.7 47.7 ± 19.5 2.5 9.7e4.6
Carotid femoral artery 1072.4 ± 366 1043.7 ± 465.2 28.7 132e189
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on blood biochemistry
 Blood sugar and lipid profile, renal function and uric acid
levels; There was no significant difference in the level of
blood sugar, lipid profile, blood urea and serum creatinine
levels between telmisartan and metoprolol groups.
Although there was a trend of greater reduction in the level
of uric acid in telmisartan group but was statistically not
significant (5.6 ± 1.2 vs. 7.2 ± 1.3, p 0.1) (Table 4).4. Discussion
Increased arterial stiffness in hypertensive patients has
prognostic importance and is mediated by inflammatory
process. Activation of local RAAS system is believed to be
one of the important trigger in initiation of inflammatory
process mediated through oxidative stress pathways.14
Thus inhibition of oxidative stress by blocking the effect of
Angiotensin- II with telmisartan which has the highest af-
finity for AT1 receptor with longest plasma half-life22e24 can
be a rational choice. In the present study telmisartan was
more effective than metoprolol in reducing arterial stiffness
in hypertensive patients; right lower limb (36.4 ± 9.6 vs.
44.8 ± 15.1 m/s, p < 0.002), left lower limb arterial stiffness of
(39.9 ± 11.7 vs. 46.8 ± 17.0 m/s, p < 0.02). There was noTable 4 e Comparison of effect of metoprolol with telmisartan
and on blood biochemistry in study groups.
Regional arterial beds Telmisartan Metoprolol Me
Right brachial artery 33.6 ± 16.8 34.3 ± 12.4
Left brachial artery stiffness 29.0 ± 7.9 32.9 ± 11.6
Right ankle arterials stiffness 36.4 ± 9.6 44.9 ± 15.1
Left ankle arterial stiffness 39.9 ± 11.7 46.8 ± 17.0
Carotid femoral artery stiffness 1011.0 ± 337.8 1045.0 ± 694.0
Fasting blood sugar 88.2 ± 11.4 90.5 ± 10.3
Total cholesterol 191.3 ± 39.9 191.2 ± 37.0
LDL-C 117.3 ± 31.8 112.9 ± 28.8
HDL-C 45.4 ± 9.4 44.2 ± 8.2
TG 163.6 ± 63.6 178.3 ± 62.0
TG/HDL-C ratio 3.8 ± 1.9 4.2 ± 1.8
Blood urea 29.1 ± 6.2 30.5 ± 7.5
S. creatinine 0.85 ± 0.10 0.86 ± 0.22
Uric acid 5.7 ± 1.2 7.2 ± 1.3
SBP 124.7 ± 7.8 129.7 ± 7.9
DBP 81.3 ± 5.4 82.4 ± 5.9
HR 78.2 ± 10.4 67.6 ± 41.5
LV mass 135.5 ± 37.6 143.2 ± 41.5significant difference between study drugs on arterial stiff-
ness in upper limb arterial bed. This could be due to lower
prevalence of increased arterial stiffness in upper limb
compared to lower limb vessels in both groups. There are
number of factors that could influence the arterial stiffness
e.g. age, sex, HR, hypertension, diabetes, dyslipidemia,
obesity, tobacco consumption status etc. Since both the
intervention groups were well matched for these con-
founders/risk factors, thus the observed decrease in PWV
with telmisartan cannot be attributed to other confounding
factors. Change in the cardiac cycle duration is likely to
affect the PWV. Studies shows increase in HR increases the
PWV25. In the metoprolol group, as expected, HR was
significantly lower than in the telmisartan group thus at the
most HR could have undermined the effect of telmisartan
on PWV as compared to metoprolol. The lack of effect of
telmisartan on arterial stiffness of carotid femoral arterial
segment observed in the study is not known. It is likely that
the structural changes in central arterial conduit vessels
may be more advanced thus needs longer duration of drug
exposure to show its reversal. Although there was a trend of
greater reduction in the LV mass in telmisartan group
(135.5 ± 37.6 vs. 143.2 ± 41.5) but was statistically not sig-
nificant. Both telmisartan and metoprolol had no significant
effect on glucose and lipid metabolism and on renal func-
tion. Telmisartan has also been found to be effective in
lowering arterial stiffness by other investigators.26,27 The
effect of telmisartan on arterial stiffness in patients withon arterial stiffness in different arterial beds, BP, LV Mass
an difference 95% C.I. of mean difference Sig. at 2 tailed
0.71 (6.6e5.2) 0.81
3.91 7.9e0.1 0.055
8.4 13.5 to 3.3 0.002
6.8 12.6 to 0.9 0.02
33.8 24.6e181.9 0.75
2.3 6.6e1.9 0.28
0.14 15.2e15.4 0.98
4.4 7.7e16.5 0.47
1.2 2.3e4.7 0.51
14.7 39.7e10.3 0.24
0.32
1.35 4.1e1.4 0.33
0.002 0.7e0.07 0.95
1.5 3.5e0.5 0.15
4.9 8.1 to 1.7 0.003
1.1 3.3e1.2 0.35
0.001
0.33
i n d i a n h e a r t j o u r n a l 6 6 ( 2 0 1 4 ) 4 1 5e4 2 1420isolated systolic hypertension where the arterial stiffness is
increased needs further studies. In present study, popula-
tion with isolated systolic hypertension formed the very
small group (<3%) thus observation made in present study
cannot be translated into this subset of hypertensive pa-
tients. It would also be of interest to evaluate the correlation
between changes in cardiac loading conditions due to
changes in arterial stiffness in response to different anti-
hypertensive agents on regional myocardial systolic and
diastolic function with use of more sensitive tools e.g. strain
imaging with speckle tracking methods. These observations
may help improving our mechanistic understanding of
impact of arterial stiffness on cardiac function and would
form the basis for making informed decision in selection of
antihypertensive drugs in future.5. Conclusions
Telmisartan was more effective in lowering arterial stiffness
in lower limb vessels compared to metoprolol in newly
detected and known hypertensive patients not on antihyper-
tensive medications.6. Study Limitations
 Small sample size limited the statistical power to detect
true differences between metoprolol and telmisartan on
arterial stiffness in upper limbs, LV mass.
 Findings are not generalizable to patients with isolated
systolic hypertension.
 Study exposure period of six months probably may be
inadequate to bring significant impact on structural
remodeling of arterial wall favorably.Conflicts of interest
All authors have none to declare.r e f e r e n c e s
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